SNPHF (Santen Pharmaceutical Co) Ending Cash Position: $122 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHF Santen Pharmaceutical Co Ltd SNPHF
75 GF Score
Price $13.05
GF Value $10.20
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Santen Pharmaceutical Co Ending Cash Position?

Santen Pharmaceutical Co SNPHF +4.40% 75 Ending Cash Position is $122 Mil as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 75/100 and a GF Value™ of $10.20 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Santen Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2026 was $122 Mil.

Santen Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2025 ($-142 Mil) to Dec. 2025 ($395 Mil) but then declined from Dec. 2025 ($395 Mil) to Mar. 2026 ($122 Mil).

Santen Pharmaceutical Co's annual Ending Cash Position declined from Mar. 2024 ($631 Mil) to Mar. 2025 ($0 Mil) but then increased from Mar. 2025 ($0 Mil) to Mar. 2026 ($510 Mil).

Santen Pharmaceutical Co Ending Cash Position Related Terms

Santen Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Ending Cash Position Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 700.08 433.20 631.31 0.00 509.67

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 585.38 -142.15 394.73 121.82
SNPHF
75GF Score
Santen Pharmaceutical Co Ltd SNPHF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Santen Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=586.056+-76.391
=510

Santen Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.001000000000019+121.821
=122

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $122 Mil mean?
Santen Pharmaceutical Co (SNPHF) has a Ending Cash Position of $122 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Ending Cash Position too high?
Santen Pharmaceutical Co's current Ending Cash Position is $122 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Ending Cash Position compare to LLY and JNJ?
Santen Pharmaceutical Co's Ending Cash Position of $122 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Ending Cash Position is $122 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.20, compared to a current price of $13.05 — trading 27.9% above its estimated fair value. The current Ending Cash Position is $122 Mil. Santen Pharmaceutical Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Ending Cash Position is $122 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.9% above its estimated GF Value™ of $10.20. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Ending Cash Position: $122 Mil
  • GF Value™: $10.20 vs. price of $13.05 (27.9% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
75GF Score

Get the complete analysis for SNPHF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.20
GF Value